mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
Sebastianutto, Irene LU and Cenci, Maria Angela LU
(2018)
In Current Opinion in Pharmacology
38.
p.81-89
- Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets... (More)
Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets in PD and LID. We here review the antiparkinsonian and antidyskinetic potential of modulating group I, II, and III mGluRs in several preclinical models of PD. We also provide an update on clinical trials evaluating mGluR5 or mGluR4 ligands in PD.
(Less)
- author
- Sebastianutto, Irene
LU
and Cenci, Maria Angela
LU
- organization
- publishing date
- 2018-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Opinion in Pharmacology
- volume
- 38
- pages
- 9 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85044742293
- pmid:29625424
- ISSN
- 1471-4892
- DOI
- 10.1016/j.coph.2018.03.003
- language
- English
- LU publication?
- yes
- id
- 231b3e1e-4105-415a-ad20-085d4b9af7f7
- date added to LUP
- 2018-04-11 14:40:43
- date last changed
- 2024-04-15 06:21:33
@article{231b3e1e-4105-415a-ad20-085d4b9af7f7,
abstract = {{<p>Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor features that result from dopamine (DA) depletion in the striatum. DA replacement therapy with L-DOPA is the most efficacious symptomatic treatment, but causes complications that limit its utility, in particular, L-DOPA-induced dyskinesia (LID). LID is primarily caused by pre-synaptic and post-synaptic changes in DA neurotransmission, although it also depends on altered glutamatergic transmission at several nodes of the cortico-basal ganglia-thalamocortical network. The important functional interplay between dopaminergic and glutamatergic systems has stimulated an interest in metabotropic glutamate receptors (mGluRs) as potential therapeutic targets in PD and LID. We here review the antiparkinsonian and antidyskinetic potential of modulating group I, II, and III mGluRs in several preclinical models of PD. We also provide an update on clinical trials evaluating mGluR5 or mGluR4 ligands in PD.</p>}},
author = {{Sebastianutto, Irene and Cenci, Maria Angela}},
issn = {{1471-4892}},
language = {{eng}},
month = {{02}},
pages = {{81--89}},
publisher = {{Elsevier}},
series = {{Current Opinion in Pharmacology}},
title = {{mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia}},
url = {{http://dx.doi.org/10.1016/j.coph.2018.03.003}},
doi = {{10.1016/j.coph.2018.03.003}},
volume = {{38}},
year = {{2018}},
}